We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 106% below its sector, cheaper than its peers on earnings.
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 2170.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
